Literature DB >> 12712439

Molecular detection of p16 promoter methylation in the serum of recurrent colorectal cancer patients.

Hiroshi Nakayama1, Kenji Hibi, Tsunenobu Takase, Taiji Yamazaki, Yasushi Kasai, Katsuki Ito, Seiji Akiyama, Akimasa Nakao.   

Abstract

We previously proved that p16 promoter methylation present in the tumors of colorectal cancer patients can be detected in the serum of those same patients using methylation-specific PCR (MSP). To seek the possibility that this technique could be applied to the monitoring of cancer recurrence, we examined the p16 methylation using MSP. We detected tumor DNA in the serum of 31 of 45 (69%) patients with recurrent colorectal cancer. No methylation was found in serum DNA of 50 patients with colorectal cancers whose corresponding tumor DNA had no methylation in p16 promoter. These results suggested that MSP might be a sensitive and useful method to detect recurrent colorectal cancer in serum. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12712439     DOI: 10.1002/ijc.11117

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  18 in total

Review 1.  DNA methylation: its role in cancer development and therapy.

Authors:  Carla Kurkjian; Shivaani Kummar; Anthony J Murgo
Journal:  Curr Probl Cancer       Date:  2008 Sep-Oct       Impact factor: 3.187

Review 2.  How does genome sequencing impact surgery?

Authors:  Marlies S Reimers; Charla C Engels; Peter J K Kuppen; Cornelis J H van de Velde; Gerrit J Liefers
Journal:  Nat Rev Clin Oncol       Date:  2014-06-24       Impact factor: 66.675

Review 3.  DNA methylation patterns as noninvasive biomarkers and targets of epigenetic therapies in colorectal cancer.

Authors:  Yutaka Hashimoto; Timothy J Zumwalt; Ajay Goel
Journal:  Epigenomics       Date:  2016-04-22       Impact factor: 4.778

4.  Detection of DNA hypermethylation in remote media of patients with colorectal cancer: new biomarkers for colorectal carcinoma.

Authors:  Andreas Herbst; Frank T Kolligs
Journal:  Tumour Biol       Date:  2012-02-24

5.  Correlation between T-cadherin gene expression and aberrant methylation of T-cadherin promoter in human colon carcinoma cells.

Authors:  Jian-Zhen Ren; Ji-Rong Huo
Journal:  Med Oncol       Date:  2011-02-05       Impact factor: 3.064

Review 6.  Epigenetics of colorectal cancer.

Authors:  Ajay Goel; C Richard Boland
Journal:  Gastroenterology       Date:  2012-09-20       Impact factor: 22.682

Review 7.  Molecular biomarkers for the detection of metastatic colorectal cancer cells.

Authors:  Hidenori Kamiyama; Hiroshi Noda; Fumio Konishi; Toshiki Rikiyama
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

8.  Detection of hypermethylated fibrillin-1 in the stool samples of colorectal cancer patients.

Authors:  Qi Guo; Yongchun Song; Hao Zhang; Xuandi Wu; Peng Xia; Chengxue Dang
Journal:  Med Oncol       Date:  2013-08-21       Impact factor: 3.064

Review 9.  DNA methylation aberrancies delineate clinically distinct subsets of colorectal cancer and provide novel targets for epigenetic therapies.

Authors:  D J Weisenberger; G Liang; H-J Lenz
Journal:  Oncogene       Date:  2017-10-09       Impact factor: 9.867

Review 10.  Use of blood-based biomarkers for early diagnosis and surveillance of colorectal cancer.

Authors:  Ganepola Ap Ganepola; Joel Nizin; John R Rutledge; David H Chang
Journal:  World J Gastrointest Oncol       Date:  2014-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.